Media.Player

Diabetes Imaging Agent

Technology Benefits

Improve early diagnosis, help monitor disease progression, provide tools to measure responsiveness to therapy and evaluate the efficiency of islet transplantation and graft survival.

Technology Application

Method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. Diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.

Detailed Technology Description

D2 receptors (D2R) for dopamine were recently reported on rodent and human islets. University of California researchers propose to use a commercially available ligand with sub-nanomolar affinity and a high degree of specificity for D2R/D3R radiolabeled with fluorine-18 (half-life = 110 minutes) as a positron emission tomography (PET)-scanning agent to quantify changes in β-cell mass associated with diabetes mellitus. The fluorine-18 (18F) radioligand for dopamine D2 receptors (D2R) will be injected into diabetic patients. The radioligand will bind to the D2Rs in islets allowing the radioactive uptake by PET-CT scanning. Loss of beta cells will result in loss of radioligand binding to the pancreas. Since uptake of the radioligand in the liver is low, it may be feasible to detect small changes in the pancreas due to reduced background interference. The use of fluorine-18 as a radiolabel allows the use of the radioligand at facilities that do not have a cyclotron. Furthermore, the ligand is approved for human use making it eminently suitable as a diagnostic tool for T1DM.

Supplementary Information

Patent Number: US20080319310A1
Application Number: US2008110135A
Inventor: Mukherjee, Jogeshwar | Chandy, George | Milne, Norah | Wang, Ping H. | Easwaramoorthy, Balu | Mantil, Joseph
Priority Date: 26 Apr 2007
Priority Number: US20080319310A1
Application Date: 25 Apr 2008
Publication Date: 25 Dec 2008
IPC Current: A61B0005055
US Class: 600420
Title: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Usefulness: Imaging Agents For Monitoring Changes Of Dopamine Receptors And Methods Of Using Thereof
Summary: The method is useful for monitoring changes in beta cell mass in a patient, where the patient is at preclinical or clinical stage of diabetes such as Type I or Type II diabetes (all claimed).
Novelty: Non-invasive method for monitoring changes in beta cell mass in subject, involves detecting level of dopamine receptor in pancreas of subject

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

9662059

Others

Tech ID/UC Case

19364/2007-169-0

Related Cases

2007-169-0

*Abstract

The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes to monitor disease progression or treatment efficacy of candidate drugs.

*IP Issue Date

May 30, 2017

*Principal Investigator

Name: Philippe Azam

Department:

Name: George Chandy

Department:

Name: Balu Easwaramoorthy

Department:

Name: Joseph Mantil

Department:

Name: Norah Milne

Department:

Name: Jogeshwar Mukherjee

Department:

Name: Ping Wang

Department:

Country/Region

USA